Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Celldex Therapeutics (CLDX) Cost of Revenue (2024 - 2025)

Celldex Therapeutics has reported Cost of Revenue over the past 6 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $1.2 million for Q4 2025, down 23.92% from a year ago — trailing twelve months through Dec 2025 was $6.0 million (up 6.88% YoY), and the annual figure for FY2025 was $6.0 million, up 6.88%.
  • Cost of Revenue for Q4 2025 was $1.2 million at Celldex Therapeutics, up from $1.1 million in the prior quarter.
  • Over the last five years, Cost of Revenue for CLDX hit a ceiling of $2.2 million in Q1 2025 and a floor of $1.1 million in Q3 2025.